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Longitudinal evaluation of peritoneal macrophage function and acti-
vation during CAPD: Maturity, cytokine synthesis and arachidonic acid
metabolism. The release of cytokines and prostaglandins (PG) by perito-
neal macrophages (PM0) may influence the cytokine network controlling
peritoneal inflammation and in the long-term the function of the perito-
neum as a dialysis membrane. In the present study, an evaluation of the
long-term effects of peritoneal dialysis on the release of cytokines and
prostaglandins, and the expression of surface markers of cellular matura-
tion on blood and mononuclear cells has been performed in patients
during their first year on CAPD. Spontaneous release of tumour necrosis
factor a (TNFa) and interleukin 6 (IL-6) by PMØ, after 4 or 24 hours in
culture, increased significantly with time on CAPD, while there was a
small but significant decrease in release of prostaglandin E2 (PGE2).
Production of TNFa and IL-6 was enhanced following incubation of the
cells with lipopolysaccharide (LPS), but the effect of LPS was proportion-
ally greater on blood monocytes than on PMØ. There was a significant
increase in the concentrations of PGE2 and 6-keto-prostaglandin F1 in
overnight dwell peritoneal dialysis effluent with time on CAPD. The levels
of TNFa and IL-6 in uninfected PDE were below the detection limit of the
immunoassay over the whole time period studied. Expression of CD15,
which correlates with immaturity, by PMØ and blood monocytes increased
with time on CAPD, while expression of CD11c, a marker of maturation,
decreased on blood monocytes, but did not change significantly on PMØ.
There was also a slight increase in expression of transferrin receptor in
both PMØ and monocytes, but this did not reach statistical significance.
These findings suggest that peritoneal macrophages and blood monocytes
isolated from CAPD patients over a one year period become increasingly
immature with time, and this is accompanied by a significant modulation
of their ability to secrete inflammatory cytokines. Dysregulation of mac-
rophage function may have important consequences with respect to
inflammatory processes and the long-term function of the peritoneal
membrane in CAPD patients.
Continuous ambulatory peritoneal dialysis (CAPD) is now
widely used in the treatment of end-stage renal failure. Its
increasing use, however, has highlighted the fact that the function
of the peritoneal membrane as a dialyzing organ may be adversely
affected by long term exposure to the CAPD environment. In
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particular, loss of ultrafiltration [11 and changes in the morphol-
ogy of the peritoneum [2] can occur after extended treatment
periods, even in patients with no history of peritonitis [3—6]. There
is also evidence that immunological changes occur within the
peritoneum after the initiation of CAPD [71. Several studies have
demonstrated that PMØ become increasingly immature [8—14],
have reduced bactericidal activity as well as increased chemotactic
activity and transferrin receptor expression (TfR) compared with
controls [8—111. In addition Betjes et al [14] have recently shown
that, compared with cells from normal controls, PMØ from
CAPD patients not only had a less mature phenotype, as mea-
sured by RFD7 expression, but also showed signs of chronic
activation as evidenced by their increased expression of Fe
receptors.
Fieren, van den Bemd and Bonta [151 have demonstrated that
PMØ isolated from patients with peritonitis are primed for
cytokine release following lipopolysaccharide (LPS) stimulation,
suggesting that these cells are already in a semi-activated state in
vivo and only require a second stimulus to become fully activated.
It is not known, however, whether PMØ isolated from uninfected
CAPD patients show changes in their constitutive and stimulated
ability to release cytokines and prostaglandins with increasing
time on CAPD.
The present longitudinal study was therefore initiated to exam-
ine the potential effects of peritoneal dialysis on: (a) the release by
PMØ of the cytokines tumor necrosis factor alpha (TNFa) and
interleukin-6 (IL-6) both constitutively and after in vitro stimula-
tion; (b) the release of prostaglandins (PGE2 and 6-keto-PGF1,)
by PM0; (c) the levels of cytokines and prostaglandins in perito-
neal dialysis effluent (PDE); and (d) the expression of surface
markers of cellular maturation on PMØ and peripheral blood
mononuclear cells (MNC).
Our data indicate that PMØ isolated from CAPD patients over
a one year period become increasingly immature as assessed by
surface marker expression. This is accompanied by a significant
modulation of their ability to secrete inflammatory cytokines and
prostaglandins (PG). Long-term dysregulation of PMØ function
may have important consequences and might contribute to the
loss of peritoneal membrane function seen in some CAPD
patients after long periods on this form of therapy.
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Table 1. Details of patients in group I
Patient Sex Age System
Time at which
last sample
was taken, months
No. of peritonitis Underlying
episodes/cause disease
Reason for patient
being eliminated
before 12 months
1 F
2 M
3 F
4 M
5 M
6 M
7 M
8 F
9 F
10 F
11 M
12 M
71
17
54
52
75
67
66
44
69
30
17
58
Fres.
Bax.h
Fres.
Bax.
Bax.
Fres.
Bax.
Bax.
Bax.
Bax.
Bax.
Bax.
12
12
12
3
9
9
12
9
12
12
12
6
(1) enterococcus Etiology unknown
(1) coagulase negative
Staphylococcus
(1)S. aureus Hypoplastic renal disease
(0) Renovascular disease
(1)S. epidermidis Diabetic nephropathy
(1) S. epidermidis Glomerulonephritis
(0) Glomerulonephritis
(0) Etiology unknown
(0) Diabetic nephropathy
(0) Etiology unknown
(0) Etiology unknown(1) S. aureus Obstructive nephropathy
(1) S. epiderinidis Diabetic nephropathy
—
—
—
Changed to hemodialysis
Died
Died
—
—
—
—
—
Changed to hemodialysis
Fresenius AndyhBaxter Solo
Table 2. Details of patients in group 2
Patient Sex Age System
Time at which
last sample
was taken, months
No. of peritonitis Underlying
episodes/cause disease
Reason for patient
being eliminated
before 12 months
1 F
2 F
3 F
4 M
5 M
6 M
7 F
8 M
9 M
10 F
56
32
33
58
55
43
69
18
66
12
Bax.°
Fres.6
Fres.
Fres.
Bax.
Bax.
Bax.
Fres.
Bax.
Bax.
12
12
6
12
12
9
9
3
12
12
(1) mixed Glomerulonephritis
(2)S. aureus Wegener's granulomatosis
(0) Interstitial nephritis
(0) Diabetic nephropathy
(1) 5. epidermidis Diabetic nephropathy
(0) Glomerulonephritis
(2) S. epidermidis Diabetic nephropathy
(0) Congenital hypoplastic
renal disease
(0) Glomerulonephritis
(2)S. aureus, Polycystic kidneys
S. epidermidis
—
—
Transplanted
—
—
Changed to hemodialysis
Died
Transplanted
—
—
a Fresenius Andyh Baxter Solo
Methods
Patients
Two separate trials were conducted, involving a total of 22
patients commencing CAPD, 12 patients in group 1 (Table 1) and
10 in group 2 (Table 2). The first sample was obtained on the day
of commencement of dialysis and subsequent samples at one week
(group 1 only) and 1, 3, 6, 9 and 12 months. In group 1, 8 patients
were monitored for the full period and 6 of those in group 2. Study
of the remaining patients was terminated earlier for a variety of
reasons (Tables 1 and 2). A total of 7 (group 1) and 8 (group 2)
episodes of peritonitis occurred among these patients during the
study; all (except group 1, patient 11 at 3 months) occurred at
least three weeks before the time when a sample was due to be
taken. To ensure that these episodes of peritonitis did not affect
the results, the parameters examined were analyzed separately for
patients with and without peritonitis. In no case was a significant
difference found (data not shown).
Peritoneal equilibrium test (PET). A four-hour hypertonic ex-
change was performed in each patient at each time interval after
one month from the start to assess ultrafiltration. Blood biochem-
istry was analyzed at the time of each sample to monitor the
efficiency of CAPD.
Cell cultures
All the following processes were carried out in a laminar flow
cabinet and all buffers and media, etc., had < 12.5 pg/mI con-
tamination with endotoxin.
Peritoneal cells. Overnight PDE was spun in an MSE Mistral
centrifuge in 1 liter bottles at 500 X g for 15 minutes. For group
I the supernatants were removed and stored in aliquots at —70°C
until needed for analysis of cytokine and prostaglandin levels. The
cells from patients in group 1 were resuspended (106 cells/mI) in
Ham's F12 medium (ICN Flow Biomedicals Ltd. Rickmansworth,
UK) supplemented with penicillin (100 U/mI), streptomycin (100
.tg/ml), transferrin (5 .tg!ml), insulin (5 xgIml) and hydrocorti-
sone (0.4 g/ml; all from Sigma, Poole, UK) and 10% fetal calf
serum (FCS; ICN Flow). These cells were used for testing
constitutive cytokine and PG release. Cells from group 2 patients
were resuspended in RPMI 1640, supplemented with penicillin,
streptomycin, and FCS as above. Cells from this group were used
to measure cytokine release from LPS-stimulated PMØ and also
for surface marker studies. Viability, determined by eosin exclusion,
was always > 95%. Ham's F12 medium was used for culturing cells
from group 1 patients as the supernatants were subsequently added
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to mesothelial cell cultures, which require this medium [161. Other-
wise RPMI 1640 was used as in our previous work with PMØ [8].
Blood mononuclear cells. Blood mononuclear cells were ob-
tained from the group 2 patients at the same time as the PMØ and
were isolated by centrifugation of heparinized blood over Lym-
phoprep separating mixture (Nycomed UK Ltd., Birmingham,
UK). The cells were removed from the interface layer, washed
twice and resuspended at 106 cells/ml in RPMI 1640 medium with
10% fetal calf serum.
Preparation of macrophage supernarants from group 1. Peritoneal
cells (2 x 106 in 2 ml) were cultured in 35 mm diameter Petri
dishes for two hours at 37°C/5% CO2 to allow adherence of the
PMØ. The dishes were then washed twice with warm Ham's F12,
the number of non-adherent cells removed in the washings was
counted and the number of adherent cells calculated by the
difference. Fresh medium (2 ml) was then added to each Petri dish
and the incubation continued for a further two hours. The
supernatants were then removed and stored in 1 ml aliquots at
—70°C until analysis. A further 2 ml of fresh medium was added
and cells incubated for a further 20 hours, at which time the
supernatants were again collected and stored as above. It should
be noted that, in this trial, no external stimulus such as LPS was
added to the cells.
Preparation of rnacrophage and monocyte supernatants from
group 2. Aliquots of each above cell suspensions were plated in
24-well plates, non-adherent cells removed after two hours, and
the cells then incubated with or without 2 gig/mI of lipopolysac-
charide from E coli 055.B5 (LPS, Difco, Detroit, MI, USA) in 1 ml
of RPMI 1640/10% FCS for 22 hours. Supernatants were then
removed, filtered, and stored at —70°C.
Cell surface marker analysis. Peritoneal cells from the second
group of patients were incubated in separate 200 .d aliquots for 30
minutes with monoclonal mouse antibodies to transferrin recep-
tor, CD11c and CD15 (all from Serotec). A F(ab')2 rabbit anti
mouse FITC conjugate (Serotec) was used as second antibody and
the proportion of macrophages and lymphocytes staining positive
determined by FACS. Mononuclear cells in peripheral blood
obtained from the patients at the same time as PDE were
analyzed using Q-Prep (Coulter Electronics Ltd., Luton, UK), a
whole blood lysis method, and the same antibodies. The propor-
tion of monocytes and lymphocytes reacting with each antibody
was determined.
Cytokine and prostaglandin assays
TNFn and IL-6 were measured by enzyme immunoassay [17—19]
and prostaglandin E2 (PGE2) and 6-keto-prostaglandin F1 (PGF1,)
by radioimmunoassay [16, 17, 20] as previously described.
Statistics
Statistical analyses were performed using Minitab (Minitab
Inc., State College, PA, USA). If necessary, a logarithmic or a
square root transformation was applied to the observations so that
they approximated to a normal distribution. The logarithm of the
time on dialysis was used when needed to make the sampling
interval more uniform. Changes in variables with time on dialysis
were estimated by linear regression. Before performing linear
regression analyses, the data were adjusted by analysis of variance
to have the same grand mean for each patient and for each batch
of samples, after which the data were pooled. Degrees of freedom
were adjusted accordingly. A paired r-test was performed to test
for an absolute difference in cytokine concentration due to
different experimental treatments of the same cell preparation,
irrespective of source. For the t-test, observations were pooled by
taking the grand mean for all the observations, and the effect of
batches, patients and time on cytokine release removed by adding
to the grand means the residuals from analysis of variance.
Degrees of freedom were adjusted by subtraction of the number
of batches, patients and sampling times in the study. A critically
significant level of P = 0.05 was used throughout the study.
Results are given as the mean the standard error of the mean.
Results
Patient parameters
No significant changes were seen in creatinine, urea or ultrafil-
tration values. Initially values were 738 97 mol/liter, 24.2 2.4
mmol/liter and 670 83 ml, respectively. After one year they were
1042 120 imol/liter, 21.1 6.8 mmol/liter and 700 82 ml,
respectively (P = NS by linear regression, N = 12 at day 1 and 8
at 1 year).
Cytokines and prostaglandins in PDE
Prostaglandins. The mean levels of both PGE2 and 6-keto-
PGF1 in PDE at the beginning of the study were 2.35 0.1 ng/ml
and 0.87 0.1 ng/ml, respectively (Fig. 1). A significant rise in the
levels of both PGs with time on CAPD was observed (P < 0.001
by linear regression, N = 12 at day 1 and 8 at 1 year).
Cytokines. The levels of TNFn and IL-6 were generally at or
beneath the detection limit of the assay (20 and 40 pglml for TNFa
and IL-6, respectively) throughout the whole time course measured.
There was thus no evidence of any change with time on CAPD.
Cytokine and prostaglandin synthesis by PMØ
The constitutive levels of TNFa and IL-6 secreted by PMØ
after both 4 or 24 hours in culture increased significantly with
increasing time on CAPD (Fig. 2; P < 0.01 for IL-6, P < 0.001 for
TNFs by linear regression, N = 12 at day 1 and 8 at 1 year). After
four hours constitutive secretion of TNFa increased from 167
106 at day 1 of treatment to 645 338 pg/b6 PMØ after one year
therapy, and for IL-6 from 164 75 to 464 119 pg/106 PMØ.
After 24 hours in culture PMØ TNFa levels were 74 43 and 388
187 pg/b6 PMØ at day 1 and one year, respectively, and the
corresponding numbers for IL-6 were 331 187 and 929 403
pg/b6 PMØ. The levels of IL-6 secreted by PMØ after 24 hours
were always greater than those at four hours irrespective of the
patient or time on CAPD, while for TNFa the reverse was true
(P < 0.001 by paired t-test in both cases, N = 62). No significant
changes in the constitutive secretion of PGs by PMØ was observed
with time on CAPD, other than a significant (P < 0.05 by linear
regression) decrease in PGE2 production by PMØ after four
hours of culture (data not shown).
Stimulated cytokine and prostaglandin release in PMØ amd MNC
Constitutive TNFa and IL-6 synthesis by PMØ was always
significantly greater than by MNC, irrespective of treatment time
(P < 0.01 by paired t-test, N = 49), the mean values for TNFn and
IL-6 being respectively 106 21.5 and 13704 1593 pg/106 cells
for PMØ, and 46.7 12.5 and 4119 922 pg/106 cells for MNC,
respectively. In contrast, the effect of LPS stimulation on cytokine
production was significantly greater on peripheral blood MNC
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Days on dialysis
Fig. 1. Levels of PGE2 (A) and 6-keto-PGF1 (B) in peritoneal dialysis
effluent from patients on CAPD from day of commencement up to one year.
Each point represents the mean value of duplicate determinations.
P < 0.001.
than on PM0 isolated from the same patient (P < 0.001 for TNFa
and IL-6, respectively, by paired 1-test, N = 47).
At the start of the study, LPS-stimulated TNFs and IL-6 levels
produced by MNC were 35.5 3.58 and and 165.3 7.3 pg/106
cells, respectively. There was an increase in both cytokines with
time on CAPD, but only in the case of TNFa was this statistically
significant (P < 0.05 by linear regression). The difference in
cytokine production between unstimulated and LPS-stimulated
MNC also increased with time on CAPD (Fig. 3 A, B; P < 0.05
and P < 0.002 for TNFa and IL-6, respectively, by linear
regression, N = 48).
The initial levels of TNFcr and IL-6 produced by LPS-stimu-
lated PMØ were 29.9 3.1 and 157 11.1 pg/b6 cells,
respectively. There was no significant change in the levels with
time on CAPD, and there was also no significant change in the
relative increase over production by unstimulated cells (Fig. 3 C, D).
Cell surface expression of markers of maturity
The proportion of PMØ exprcssing CD15 increased signifi-
cantly with time on CAPD (Fig. 4B, P < 0.05 by linear regression,
N = 10 at day I and 6 at 1 year). At time zero 16.1 2.4% of
PMØ expressed this marker, and this increased to 36.9 6.2%
after one year on CAPD. The mean expression by PMØ of CD1Ic
decreased slightly (Fig. 4A) and that of the TfR (Fig. 4C)
increased slightly, but neither of these changes were statistically
significant.
In peripheral blood MNC, the expression of CD11c decreased
significantly with time on CAPD from a mean of 23.0 10.6% at
day I to 10.2 2.3% after one year (Fig. 5A; P < 0.05 by linear
regression, N = 10 at day 1 and 4 at 1 year). In contrast, the mean
percent expression of CD15 increased significantly (P < 0.05; Fig.
5B) from 25.7 5.3% at day I to 49.0 3.1% after one year. The
level of MNC TfR expression (Fig. 5C) did not change significantly.
Discussion
The process of CAPD is dependent on the long term function
of the peritoneal membrane as a dialysing organ. Loss of function
of this membrane related to repeated infection or to long term
changes in its structure/function can in some cases lead to a
change of renal replacement therapy. The mechanisms by which
loss of membrane function, as manifested by loss of ultrafiltration,
are initiated remain poorly understood, although it has been
suggested that chronic inflammatory activation within the perito-
neal cavity might be important in its etiology [21]. The present
study was therefore initiated to examine the function and maturity
of PMØ and peripheral blood MNC isolated from patients over
their first year on CAPD.
Previous studies by ourselves and others have indicated that
PMØ maturity and function might be altered in patients exposed
to long term CAPD [8—11, 14]. In the present study the expression
of CD15 (a marker of cell immaturity [22—241) by PMØ and MNC
was significantly increased and the expression of CD11c (a marker
of cell maturity [251) by peripheral blood MNC was significantly
reduced.
There was also a slight increase in transferrin receptor expres-
sion (CD71; a marker of cell immaturity and/or activation [12,
13]) by both PMØ and MNC with time on CAPD, which did not
reach statistical significance in either case. It is possible that had
the study been larger this relationship would have become signif-
icant, as we have previously reported in a larger number of
randomly selected patients [9]. The decrease with time of CD11c
expression by MNC supports the concept that the pool of
monuclear phagocytes, the precursors of PMØ, is becoming
increasingly immature. The CD11c group of integrins is important
in MNC phagocytosis [26] and a decrease in its expression might
render cells less able to mount an adequate response to bacterial
invasion. In this respect a recent study by Betjes et al [27] has
demonstrated a malfunction in immunophagocytosis by PMØ
immediately prior to the onset of peritonitis.
This increasing immaturity of macrophages and monocytes may
explain the results of an earlier study in which the ability of
peritoneal cells to kill Staphylococcus epidermidis decreased with
time on CAPD [28]. Further support for the immaturity of CAPD
macrophages comes from the work of Goldstein et al [11], who
suggested that PMØ are relatively immature monocytes freshly
derived from bone marrow, based on increased chemotaxis and a
lower eicosanoid precursor uptake compared with controls. Fur-
thermore, Davies et al [29] found expression of RFD7, a marker
of mature tissue macrophages with phagocytic potential, was
relatively low on CAPD macrophages, suggesting curtailment of
the maturation process, perhaps due to rapid cell turnover [11].
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The present study demonstrated increased potential for PMØ
to synthesize cytokines (TNFa and IL-6) cx vivo with increasing
time on CAPD. Although the mechanism underlying this dysregu-
lation of cell function is unclear, it is possible that the increasing
immaturity of PMØ with time on CAPD results in a loss of the
normal control mechanisms regulating cytokine production. It is
known that the release of cytokines from leukocytes is affected by
their state of maturation, as well as by activation and/or differen-
tiation [30, 31]. In a recent study, Friedlander et a! [32] also found
that the constitutive production of PGE2 and IL-6 in PMØ from
CAPD patients was higher than in control cells, which provides
evidence that during CAPD chronic inflammatory stimulation of
PMØ occurs, and that this may be related to duration of treat-
ment. The effect of LPS on cytokine synthesis by PMØ did not
change with time on CAPD, whereas with monocytes an increase
did occur. Bos et a! [33] have suggested that CAPD changes the
normal resident cell population of the peritoneum to an exudate
macrophage population, which would indicate that a state of
chronic inflammation exists. Nevertheless, inflammatory exudate
macrophages may in any case be relatively immature cells [34], 50
it is possible that both hypotheses are correct. Betjes et al [14]
have shown that PMØ from CAPD patients show simultaneous
characteristics of immaturity and activation, with expression of
a less mature phenotype as measured by RFD7 expression but
a higher Fc receptor expression. They also showed that the
peritoneal immune system stays at a higher level of activation
in high peritonitis-incidence patients which could account for
the damage done to the peritoneum after frequent episodes of
peritonitis. It should be noted that none of the patients on the
present study suffered more than two episodes of peritonitis during
the year long study, so none can be considered high peritonitis-
incidence patients.
Mesothelial cells have been shown to synthesize IL-6, IL-8, IL-i
and prostaglandins [18, 35, 36], and it is possible that if TNFn is
produced by the PMØ in vivo it could stimulate mesothelial cells,
thus altering regulation of the cytokine network [18, 21, 36]. Also
of interest is the finding that the levels of IL-6 produced by PMØ
were always higher at 24 hours than at four hours after isolation,
but for TNFa the reverse was true. This accords with the generally
accepted idea that TNFcs is produced before IL-6 in an immune
response [37]. In this respect the recent study by Zemel et a! [38]
demonstrates that the levels of TNFa are elevated at the onset of
peritonitis while the levels of IL-6 are maximal at a later stage of
infection. Recent evidence suggests that IL-6 may be anti- rather
A 4 hr B 4 hr
SS
P<0.01
E
c.
(0
E00
10
0.1
0.001
10
.
C
Days on dialysis
0.1
0.001
10
0.1
0.001
P<0.001
1 10 100
Days on dialysis
.
D
E0
P<0.01
1 10 100
0.1
0.001
Days on dialysis Days on dialysis
Fig. 2. Levels of IL-6 (A, C) and TNFr (B, D) in culture supernatants of unstimulated PMØ after 4 (A, B) and 24 (C, D) hours in culture. The cells were
taken from CAPD patients over a one year period from the day of commencement. Each data point represents the mean value of duplicate
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Fig. 3. The calculated difference between constitutive and LPS-stimulated cytokine levels produced by peripheral blood MNC and PMØ isolated from CAPD
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Fig. 4. Change in expression of CDIJ (A), and
CDJ5 (B) and TfR (C) by PMØ from patients
on CAPD, from day of commencement up to one
year. Each data point represents a single
determination using PMØ isolated from each
patient. (A, P = NS; B, P < 0.05; C, P = NS)
than pro-inflammatory as it can suppress the expression of mRNA
for other cytokines [39, 401. In this context IL-6 could act as a
negative feedback signal for the production of cytokines by PMØ,
thus controlling the inflammatory response.
No significant change in the levels of IL-6 or TNFa in the PDE
with time on CAPD was detected but levels were generally at the
detection limit of the assay. However, a significant increase did
occur in the levels of PGE2 and 6-keto-PGF1,, in PDE. Neverthe-
less, production of prostaglandin or prostacyclin in vitro by
cultured PMØ did not change with time on CAPD, suggesting that
the changes found in PDE reflect increased secretion by the other
resident peritoneal cells. In this respect the mesothelium may be
a major source of prostaglandins in the peritoneal cavity and it is
likely that the PMØ themselves can directly elevate mesothelial
cell arachidonic acid metabolism, at least partly, as a result of their
secretion of TNFa [20, 36, 41—431.
The data presented in this study present evidence that over a
one year period on CAPD, PMØ become increasingly immature,
and that this is associated with an up-regulation of their secretion
of pro-inflammatory and immunomodulatory cytokines. These
results, together with the recent data of Suassuna et al [441
demonstrating significant numbers of PMØ within the peritoneal
membrane during infection-free periods, suggest that the poten-
tial for cell activation within the peritoneal membrane, mediated
by PMØ products, might increase with time on CAPD. The
relationships between changes in macrophage biosynthetic capac-
ity, inflammation and the function of the peritoneal membrane
remain to be defined. Recent evidence, however, [44] confirms
that PMØ may be in close proximity with the peritoneal mem-
brane during CAPD. It is thus possible that macrophages acti-
vated within this environment might have significant effects on the
peritoneal membrane. Although in this study we found no changes
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in ultrafiltration, it may be that within the first year it is too early
to detect such a change which only becomes evident after ex-
tended periods using this form of treatment [45j.
Although the physiological significance of our results remains
to be established, they do suggest that dysregulation of the
normally tightly-regulated inflammatory events within the perito-
neal membrane may occur, resulting in increased levels of vaso-
dilatory prostaglandins and increased macrophage activation. This
may have important consequences for the long term use of the
peritoneal membrane as a dialyzing organ.
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Appendix. Abbreviations
CAPD, continuous ambulatory peritoneal dialysis; MNC, peripheral
blood mononuclear cells; PMØ, peritoneal macrophage; PGE2, prosta-
glandin F2; 6-keto PGF1 ,, 6-keto prostaglandin F1; PDE, peritoneal
dialysis effluent; TNFa, tumor necrosis factor alpha; IL-6, interleukin 6;
PG, prostaglandin; LPS, lipopolysaccharide; FACS, fluorescence activated
cell sorter; FCS, fetal calf serum;
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